Good morning :)
$
₹
AstraZeneca PLC

AstraZeneca PLC

AZN

NYSE
Asset Logo

AstraZeneca PLC

AZN

NYSE
$189.002.78% (+5.12)
$
₹
$189.002.78% (+5.12)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $289.4B the stock is ranked 46

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

26.39
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.59
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$7.07
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.31
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

17.68%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

1.73%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
9 analysts
Hold
2 analysts
Sell
1 analyst

Price Upside

+18.5%

Earnings Growth

+114.49%

Rev. Growth

+7.83%

See Detailed Forecast

Company Profile

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
46.00
46.00
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.05
41.05
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.85
149.85
1Y Return
79.29%
79.29%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.82
30.82
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
9.89
9.89
1Y Return
12.58%
12.58%
Buy Reco %
21.42
21.42
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 18.50% growth, versus a trailing 3-year CAGR of 15.36%.

2026
Current$174.4Baseline
Analyst Target - 1 year
Target$206.66+18.5%

All values in $

202220232024202520262027$141.79$170.30$198.81Target+18.5%
2026
Current$174.4Baseline
Analyst Target - 1 year
Target$206.66+18.5%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 7.83% growth, versus a trailing 3-year CAGR of 9.82%.

2025
Current$58.73Baseline
Forecast for Dec 2026
High$64.22+9.34%
Average$63.33+7.83%
Low$61.91+5.4%

All values in $ Billion

20212022202320242025202637.4144.3545.8154.0758.73Low+5.4%Average+7.83%High+9.34%
2025
Current$58.73Baseline
Forecast for Dec 2026
High$64.22+9.34%
Average$63.33+7.83%
Low$61.91+5.4%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 114.49% growth, versus a trailing 3-year CAGR of 12.20%.

2025
Current$4.72Baseline
Forecast for Dec 2026
High$10.16+115.34%
Average$10.12+114.49%
Low$10.08+113.64%

All values in $

2021202220232024202520262.653.343.644.114.72Low+113.64%Average+114.49%High+115.34%
2025
Current$4.72Baseline
Forecast for Dec 2026
High$10.16+115.34%
Average$10.12+114.49%
Low$10.08+113.64%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

15.5
2.3
15.2
3
15.3
2.5
15.9
3
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue12.9313.5614.8913.5814.4515.1915.5015.2815.3815.99
Net Income1.921.421.52.912.452.532.323.082.503.07
Net Profit Margin14.89%10.53%10.07%21.46%16.94%16.67%15.00%20.14%16.29%19.23%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
AstraZeneca PLC 26.395.591.31
Eli Lilly and Company46.0031.351.35
Johnson & Johnson41.058.063.07
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AZN with any stock or ETF
Compare AZN with any stock or ETF
Comparing from
AZN
LLY
JNJ
Loading...

Frequently asked questions

  1. AstraZeneca PLC (AZN) share price today is $189.00 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $189.57 and a day low of $187.19.

  2. AstraZeneca PLC stock trades on NYSE under the ticker symbol AZN.

  3. AstraZeneca PLC's market capitalization is $289.36B as of November 5, 2026 at 2:29 AM IST.

  4. AstraZeneca PLC's price-to-earnings (P/E) ratio is 26.39 as of November 4, 2026.

  5. AstraZeneca PLC's price-to-book (P/B) ratio is 5.59 as of November 4, 2026.

  6. Yes, AstraZeneca PLC pays a dividend, with a current dividend yield of 1.73%.

  7. Yes, You can buy AstraZeneca PLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy AstraZeneca PLC shares in three steps: 1. Search AstraZeneca PLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since AstraZeneca PLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in AstraZeneca PLC (AZN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0529 shares at the current price of $189.00.

Loading...